Treatment of chronic hepatitis B.
Chronic infection with the hepatitis B virus (HBV) is a major cause of worldwide morbidity and mortality. A large number of therapeutic approaches has been tried, including interferon (IFN), nucleoside analogues and immunomodulators. To date controlled clinical trials have shown that only IFN is of long-term value but many patients fail to respond to treatment. New approaches to treating patients with IFN-resistant hepatitis B are currently undergoing clinical and experimental evaluation, and it seems likely that new therapeutic agents will be available in the near future.
Lok
A S
AS
Department of Medicine, Tulane University, New Orleans, LA 70112, USA.
D000998:Antiviral Agents / Q000627:therapeutic use; D002908:Chronic Disease; D006509:Hepatitis B / Q000628:therapy*; D006513:Hepatitis B e Antigens / Q000276:immunology; D006801:Humans; D007372:Interferons / Q000009:adverse effects / Q000627:therapeutic use; D007978:Levamisole / Q000627:therapeutic use
D000998:Antiviral Agents; D006513:Hepatitis B e Antigens; D007978:Levamisole; D007372:Interferons